In 2010, Ariad announced result from a stage I research of ponatinib in individuals with resistant and refractory Serious myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). This medicine may enhance your hazard of significant coronary heart or blood vessel issues (eg, heart attack, stroke), especially in individuals with https://l-glutamic-acid24578.ambien-blog.com/37377175/new-step-by-step-map-for-rifampicin